Parvin F. Peddi

发表

Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy

Matthew J. Ellis, M. Ellis, Cynthia X Ma, 2011, International journal of breast cancer.

Central nervous system toxicities of chemotherapeutic agents

D. Morgensztern, Srinivas Peddi, Parvin F. Peddi, 2014, Expert review of anticancer therapy.

Central nervous system toxicities of chemotherapeutic

D. Morgensztern, Srinivas Peddi, Parvin F. Peddi, 2014 .

Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.

S. Hurvitz, Parvin F. Peddi, R. Shatsky, 2014, Cancer treatment reviews.

PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer

S. Hurvitz, Parvin F. Peddi, 2014, Journal of Neuro-Oncology.

PARP Inhibitors in Breast Cancer: Latest Evidence

Parvin F Peddi, Parvin F. Peddi, R. Callahan, 2017, Current Breast Cancer Reports.

BRAF V600E inhibition in anaplastic thyroid cancer.

J. Glaspy, Parvin F Peddi, Parvin F. Peddi, 2013, The New England journal of medicine.

Triple negative breast cancer: any closer to cracking the code?

Parvin F Peddi, Parvin F. Peddi, 2021, Current opinion in obstetrics & gynecology.

Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma.

M. Cho, F. Gao, A. Wang-Gillam, 2013, Journal of gastrointestinal oncology.

Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.

R. McWilliams, J. Picus, A. Lockhart, 2012, JOP : Journal of the pancreas.

Management of Breast Sarcoma.

S. McCloskey, Parvin F. Peddi, C. Hsu, 2016, The Surgical clinics of North America.

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

S. Hurvitz, Parvin F. Peddi, 2014, Therapeutic advances in medical oncology.

A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2013, Clinical colorectal cancer.

Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma

A. Lockhart, M. Cho, Ling Chen, 2013, Journal of Translational Medicine.

Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer.

S. Hurvitz, Parvin F. Peddi, 2013, Future oncology.

Fertility after breast cancer treatment.

S. Orešković, M. Kasum, L. Beketić-Orešković, 2014, European journal of obstetrics, gynecology, and reproductive biology.

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.

A. Bardia, L. Spring, S. Hurvitz, 2021 .

Successful resection after neoadjuvant therapy in pancreatic adenocarcinoma.

A. Wang-Gillam, Parvin F. Peddi, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus

D. Moore, S. Hurvitz, Xiaoyan Wang, 2020, Therapeutic advances in medical oncology.

Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort

N. Wenger, L. Rosen, A. Drakaki, 2021, JCO oncology practice.

Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.

P. Fasching, R. Weinshilboum, Liewei Wang, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hormone receptor positive breast cancer: state of the art

Parvin F Peddi, Parvin F. Peddi, 2017, Current opinion in obstetrics & gynecology.

Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma

A. Wang-Gillam, Parvin F. Peddi, Jian Wang, 2013 .

Frontiers in HER2-positive breast cancer in 2020.

D. Slamon, Parvin F Peddi, Parvin F. Peddi, 2021, Current opinion in obstetrics & gynecology.

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

H. Iwata, N. Ternès, M. Campone, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.